O.D. MIKHAYLOVA¹, YA.I. GRIGUS¹, N.A. TZIRENSHCHIKOVA², A.M. NAZAROV³

¹ Izhevsk State Medical Academy, 281 Kommunarov St., Izhevsk, Russian Federation, 426034

² Municipal Clinical Hospital № 6, Ministry Health Care of Udmurt Republic, 81 Lenina St., Izhevsk, Russian Federation, 426004

³ Hospital of Ministry of Interior Affairs of Russia in Udmurt Republic, 69 Serova St., Izhevsk, Russian Federation, 426035

Mikhaylova O.D. —Cand. Med. Sc., Associate Professor of the Inner Diseases Propedeutic and Nursing Department, tel. (3412) 452072, e-mail: yagr@udmlink.ru¹

Grigus Y.I.— Cand. Med. Sc., Assistant Professor of the Inner Diseases Propedeutic and Nursing Department, tel. (3412) 452072, e-mail: yagrigus@mail.ru¹

Tzirenshchikova N.A. —Head of Gastroenterology Department, tel. (3412)687464, e-mail: niko-nadya@mail.ru²

Nazarov A.M.— Cand. Med. Sc., Head of Organization-Methodological and Treatment-Diagnostic Department, tel. (3412) 939277, e-mail: yagr@udmlink.ru³

The purpose of our work was to study of therapeutic efficacy of antisecretory drugs for treatment of exacerbation of chronic pancreatitis (CP). We examined 94 patients with CP that were divided into 3 groups: as a part of complex therapy, 38 patients received blocker histamine H2-receptor ranitidine 300 mg/day, 35 patients received proton pump inhibitor omeprazole 40 mg/day, and 21 patients received blocker M1-holinoretseptor pirenzepin (gastrotsepin) 100 mg/day. The course of treatment was 2-3 weeks. Exocrine and endocrine functions of the pancreas were evaluated in patients, and we studied the basal level of some hormones in serum to estimate the mechanism of antisecretory drugs action.

In the course of therapy we achieved reduction and then disappearing of abdominal pain and dyspeptic syndromes, which were comparable in the groups of the examined patients; reduction of acid-producing functions of a stomach, more pronounced when taking omeprazole. We found not only improvement of external and internal secretion of the pancreas (disappearing of hyperenzimemia and decreasing of insulin and C-peptide levels), but also the restoring of disturbed links between exogenous and endocrine functions. The improvement of hormone secretion of anabolic (somatotropic hormone, insulin, C-peptide, T3, T4) and catabolic (cortisol) action was revealed, which is one of the mechanisms of the positive therapeutic effect of antisecretory drugs.

Key words: chronic pancreatitis, ranitidine, omeprazole, gastrozepin, hormones.

 

 

REFERENCES

1. Gubergrits N.B., Khristich T.N. Klinicheskaya pankreatologiya [Clinical pancreatology]. Donetsk: Lebed’, 2000. 412 p.

2. Maev I.V., Kazyulin A.N., Samsonov A.A. et al. Khronicheskiy pankreatit (algoritm diagnostiki i lechebnoy taktiki). Posobie dlya vrachey obshchey praktiki, terapevtov, gastroenterologov: uchebnoe posobie [Chronic pancreatitis and others (diagnostic and therapeutic tactics). Allowance for general practitioners, internists, gastroenterologists: Textbook]. Moscow: GOU VUNMTs MZiSR RF, 2006. 104 p.

3. Steer M.L., Waxman I., Freedmann S. Chronic pancreatitis. New. Engl. J. Med, 1995, vol. 332, no. 22, pp. 1482-1490.

4. Vasil’ev Yu.V. Chronic pancreatitis: diagnosis and treatment. Lechashchiy vrach, 2005, no. 2, pp. 10-13 (in Russ.).

5. Minushkin O.N. Modern principles and algorithm of treatment of chronic pancreatitis. Materia Medica, 2003, no. 2, pp. 22-26 (in Russ.).

6. Vakhrushev Ya.M., Muravtseva O.V. Comprehensive assessment of the effect of inhibitors of acid secretion on the functional state of the stomach in peptic ulcer. Terapevticheskiy arkhiv, 2006, no. 2, pp. 35-38 (in Russ.).

7. Sheptulin A.A. Gastrotsepin in the treatment of gastrointestinal diseases. Klinicheskaya meditsina, 1996, no. 3, pp. 49-50 (in Russ.).

8. Loginov A.S., Vasil’ev Yu.V., Kas’yanenko V.I. Effectiveness of combined use of ranitidine in peptic ulcer gastrotsepin. Rossiyskiy gastroenterologicheskiy zhurnal, 1998, no. 1, pp. 28-34 (in Russ.).

9. Vasil’ev Yu.V. Bolezni organov pishchevareniya. Blokatory N2-retseptorov gistamina [Diseases of the digestive system. Blockers of histamine H2-receptor]. Moscow: Dubl’ Freyg, 2002. 93 p.

10. Grinevich V.B., Uspenskiy Yu.P., Lasyy V.P. et al. Clinical rationale for the use and effectiveness of Nexium in the treatment of chronic pancreatitis. Gastroenterologiya Sankt-Peterburga, 2002, no. 1, pp. 20-22 (in Russ.).

11. Tsimmerman Ya.S. Chronic pancreatitis : state of the art . Part II. The clinic, diagnosis, classification, treatment guidelines. Klinicheskaya meditsina, 2007, no. 2, pp. 9-14 (in Russ.).

12. Uspenskiy Yu.P., Pakhomova I.G., Bubyakina V.N. Pathogenetic substantiation prospects alginatsoderzhaschego clinical use of the drug “Gaviscon” in patients with chronic pancreatitis, combined with gastroesophageal reflux disease. Russkiy meditsinskiy zhurnal, 2007, vol. 15, no. 28, pp. 1-5 (in Russ.).

13. Vakhrushev Ya.M., Trusov V.V., Vinogradov N.A. Pechen’ i gormony [Liver and hormones]. Izhevsk, 1992. 112 p.

14. Vasil’ev Yu.V. Differentiated approach to antisecretory therapy of chronic pancreatitis , combined with ulcer or gastroesophageal reflux disease. Russkiy meditsinskiy zhurnal, 2005, vol. 7, no. 2, pp. 57-61 (in Russ.).

15. Mikhaylova O.D. Endogenous intoxication in chronic pancreatitis. Rossiyskiy zhurnal gastroenterologii, gepatologii i koloproktologii, 2010, no. 5, p. 65 (in Russ.).

16. Efimov A.S., Bezdrobnyy Yu.V. Struktura i funktsii insulinovykh retseptorov [Structure and function of the insulin receptors]. Kiev: Naukova dumka, 1987. 169 p.